On Monday November 15, 2010, 11:09 pm EST
NEW YORK (AP) — Teva Pharmaceutical Industries Ltd. said Monday its allergy treatment Qnaze met its main goal in a late-stage clinical trial.
The company said Qnaze was superior to a placebo at improving morning and evening symptoms. Patients who took the drug also had a greater response than those who took a placebo, Teva said. The most common side effect of Qnaze was nasal discomfort, which occurred at a rate similar to the placebo. There were 340 patients in the trial.
Teva is testing Qnaze as a treatment for seasonal allergic rhinitis, or inflammation caused by seasonal allergies. it is also testing Qnaze as a treatment for perennial allergies, which occur throughout the year. Qnaze is a corticosteroid that is delivered into the nose by an aerosol instead of an aqueous or “wet” spray.
Results from the study were presented at a meeting of the American College of Allergy, Asthma & Immunology in Phoenix.
Teva shares were almost unchanged at $50.74 in afternoon trading.